Inspire Medical Systems, Inc. to Participate in the Wells Fargo 2026 MedTech Innovation Spotlight

MINNEAPOLIS, June 12, 2026 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, announced today that its management team will participate in the Wells Fargo 2026 MedTech Innovation Spotlight on Friday, June 26, 2026.

GlobeNewsWire • 17 hours ago

Alphatec vs. Inspire Medical Systems: Which Healthcare Stock Is a Better Buy in 2026?

Alphatec focuses on a comprehensive spine surgery ecosystem to capture market share through integrated imaging and surgical solutions. Inspire Medical Systems dominates the sleep apnea neurostimulation market with a profitable, high-growth business model.

The Motley Fool • Jun 11, 2026

Inspire Medical: Golden Opportunity To Monetize A Fundamentally Mispriced Selloff

Inspire Medical Systems faces a sharp revenue slowdown due to temporary CPT coding and CMS Project WISeR disruptions, not fundamental business weakness. INSP maintains a robust balance sheet with ~$400M in liquidity and zero debt, providing downside insulation and supporting a 1x EV/sales valuation at depressed prices. Competitive threats from Nyxoah and GLP-1 therapies are manageable, with IP litigation successes and GLP-1s potentially expanding INSP's addressable market.

Seeking Alpha • Jun 8, 2026

Why Is Inspire (INSP) Down 15.9% Since Last Earnings Report?

Inspire (INSP) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research • Jun 3, 2026

Inspire Medical Systems, Inc. (INSP) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Inspire Medical Systems, Inc. (INSP) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Seeking Alpha • May 13, 2026

Inspire: Why I'm Still Rating The Stock A 'Sell' After The Earnings Dip

Inspire Medical Systems, Inc. remains under pressure as Q1 revenue grew just 1.6% and management slashed 2026 guidance by up to 10%. INSP faces intensifying competition from GLP-1s and rival devices, reimbursement headwinds, and coding challenges with its new Inspire 5 system. Territory contraction and a shift to supporting existing accounts signal operational headwinds and a retreat from high-growth expansion.

Seeking Alpha • May 5, 2026

Inspire Medical Q1 Earnings Beat Estimates, 2026 View Cut, Stock Down

INSP beats Q1 estimates but slashes 2026 outlook as reimbursement disruptions and WISeR program weigh on growth and procedure volumes.

Zacks Investment Research • May 5, 2026

Inspire Medical Systems, Inc. (INSP) Q1 2026 Earnings Call Transcript

Inspire Medical Systems, Inc. (INSP) Q1 2026 Earnings Call Transcript

Seeking Alpha • May 4, 2026

Inspire Medical Systems, Inc. Announces First Quarter 2026 Financial Results and Updates 2026 Guidance

MINNEAPOLIS, May 04, 2026 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire, or the Company), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, today reported financial results for the quarter ended March 31, 2026.

GlobeNewsWire • May 4, 2026

Inspire (INSP) Reports Q1 Earnings: What Key Metrics Have to Say

Although the revenue and EPS for Inspire (INSP) give a sense of how its business performed in the quarter ended March 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Zacks Investment Research • May 4, 2026